Literature DB >> 10708930

Do we need prognostic factors in nodal-negative breast cancer? Arbiter.

D F Hayes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10708930     DOI： 10.1016/s0959-8049(99)00303-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

Review 2.  Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.

Authors:  Gauri Deb; Vijay S Thakur; Sanjay Gupta
Journal:  Epigenetics       Date:  2013-04-17       Impact factor: 4.528

Review 3.  Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review.

Authors:  Ang Zheng; Lin Zhang; Ziyao Ji; Lijuan Fan; Feng Jin
Journal:  Am J Mens Health       Date:  2019 May-Jun

Review 4.  Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes.

Authors:  Yehoda M Martei; Jennifer M Matro
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.